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ABSTRACT
Objectives To investigate the temporal trends of 30- day 
mortality and hospitalisation in US Veterans with COVID-19 
and 30- day mortality in hospitalised veterans with 
COVID-19 and to decompose the contribution of changes 
in the underlying characteristics of affected populations to 
these temporal changes.
Design Observational cohort study.
Setting US Department of Veterans Affairs.
Participants 49 238 US veterans with a positive 
COVID-19 test between 20 March 2020 and 19 September 
2020; and 9428 US veterans hospitalised with a positive 
COVID-19 test during the same period.
Outcome measures 30- day mortality rate and 
hospitalisation rate.
Results Between 20 March 2020 and 19 September 2020 
and in COVID-19 positive individuals, 30- day mortality rate 
dropped by 9.2% from 13.6% to 4.4%; hospitalisation rate 
dropped by 16.8% from 33.8% to 17.0%. In hospitalised 
COVID-19 individuals, 30- day mortality rate dropped 
by 12.7% from 23.5% to 10.8%. Among COVID-19 
positive individuals, decomposition analyses suggested 
that changes in demographic, health and contextual 
characteristics, COVID-19 testing capacity, and hospital 
occupancy rates accounted for 40.2% and 33.3% of 
the decline in 30- day mortality and hospitalisation, 
respectively. Changes in the underlying characteristics of 
hospitalised COVID-19 individuals accounted for 29.9% of 
the decline in 30- day mortality.
Conclusion Between March and September 2020, 
changes in demographic and health characteristics of 
people infected with COVID-19 contributed measurably 
to the substantial decline in 30- day mortality and 
hospitalisation.
INTRODUCTION
Reports from regional health systems and the 
Centre of Disease Control suggest substantial 
temporal variations in COVID-19 mortality 
rates1–3; however, a national temporal anal-
ysis of mortality and hospitalisation rates 
accounting for individual- level characteristics 
is lacking, and the relative contribution of 
changes in demographic and health charac-
teristics of people infected with COVID-19 to 
temporal differences in mortality rates is not 
clear.
A deeper understanding of the changes in 
hospitalisation and mortality rates and the 
drivers of such changes in the first wave of the 
pandemic will aid effort to optimise manage-
ment of future waves of this global pandemic.
In this work, we leveraged the breadth and 
depth of the US Department of Veterans 
Affairs (VA) electronic healthcare databases 
to describe temporal changes in mortality 
rates and hospitalisation among COVID-
19- positive veterans, and temporal changes 
in mortality rates of hospitalised veterans 
with COVID-19. We then decomposed the 
contribution of changes in demographic, 
health and contextual characteristics to these 
temporal changes.
METHODS
Identification of COVID-19 test-positive 
individuals
Using the comprehensive COVID-19 Shared 
Data Resource (CSDR)4 5 developed by the 
Department of VA, we identified unique US 
veterans with their first laboratory- confirmed 
COVID-19- positive test between 20 March 
Strengths and limitations of this study
 ► National large- scale individual- level data from the 
US Department of Veterans Affairs which operates 
the largest integrated healthcare system in the USA.
 ► Advanced decomposition methods disentangle the 
influence of changes in demographics and health 
characteristics on temporal trends of 30- day mor-
tality and hospitalisation rates.
 ► The study accounted for important but less studied 
drivers of change in mortality and hospitalisation 
including contextual variables, testing capacity and 
hospital occupancy rates.
 ► The veteran population includes mostly older white 
men, which may limit the generalisability.
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2020 and 19 September 2020. The CSDR captures 
COVID-19 cases based on laboratory results that comply 
with Centers for Disease Control and Prevention stan-
dards, including 2019- nCOV reverse transcription- PCR 
Diagnostic Panel and the SARS- CoV-2 Multiplex Assay, 
or human- confirmed case review.5 The VA had its first 
COVID-19- positive patient on 2 March 2020. In this study, 
20 March 2020 was selected as the first day of observa-
tion where it was the first day that VA had more than 100 
COVID-19- positive patients nationally, facilitating stabi-
lisation of rate calculations. We selected 19 September 
2020 as the last day of observation to ensure 30 days of 
follow- up for observation of outcomes.
Data sources
Data were obtained from the VA CSDR4 and Corporate 
Data Warehouse (CDW),6–18 which provides electronic 
health record information during routine healthcare. 
Demographic information and dates of death were 
collected from the CDW SPatient domain. Patient clin-
ical diagnoses, procedures and hospitalisation character-
istics were obtained from the CDW outpatient encounter 
and inpatient encounter domains. Smoking status was 
obtained from the CDW health factors domain. Labora-
tory results, including serum creatinine, were obtained 
from the CDW patient laboratory chemistry domain. Data 
on height, weight and blood pressure were procured from 
the CDW vital signs domain. The CDW outpatient phar-
macy domain was used to obtain diabetes medication data. 
The Planning System Support Group Enrollee provided 
the Federal Information Processing Standard (FIPS) 
code of residence. The 2015 Area Deprivation Index 
(ADI) were obtained from the University of Wisconsin. 
The ADI is a composite measure of a census block group’s 
socioeconomic disadvantage and is constructed from data 
elements including education, employment, housing 
quality and poverty measures.19
Outcomes
We examined the temporal trends in (1) rates of 30- day 
mortality and hospitalisation among those with a positive 
COVID-19 test, and (2) rates of 30- day mortality among 
those hospitalised with COVID-19. Thirty- day mortality 
was defined as all- cause mortality occurring within the 30 
days after the participant’s first COVID-19 positive test. 
Hospitalisation is defined by a hospital admission between 
5 days before and 30 days after the first COVID-19 positive 
test.
Participant characteristics
Race was categorised as white, black and other. Health 
features included body mass index (BMI) and smoking 
status. BMI was computed from the last measurements of 
the participant’s height and weight prior to and closest 
to the first COVID-19- positive test date. Smoking status 
was categorised as never smoker, former smoker and 
current smoker, based on the most recent record prior to 
the first COVID-19- positive test. Comorbidities included 
Table 1 Characteristics of the individuals with COVID-19 








  Age (years), median 
(IQR)
63.3 (49.8–73.1) 70.6 (61.2–76.8)
  Race, n (%)
   White 29 814 (60.6) 5054 (53.6)
   Black 16 714 (33.9) 3809 (40.4)
   Other 2710 (5.5) 565 (6.0)
  Sex (women), n (%) 5673 (11.5) 527 (5.6)
Health characteristics
  BMI category, n (%)
   Underweight (<8.5 
kg/m2)
265 (0.5) 83 (0.9)
   Normal weight 
(18.5–<25.0 kg/m2)
9939 (20.2) 1836 (19.5)
   Overweight (25–
<30 kg/m2)
15 032 (30.5) 2922 (31.0)
   Obesity (>18.5 kg/
m2)
24 002 (48.7) 4587 (48.7)
  Smoke, n (%)
   Never smoker 27 492 (55.8) 4713 (50.0)
   Former smoker 13 062 (26.5) 2956 (31.4)
   Current smoker 8684 (17.6) 1759 (18.7)
  Hypertension, (%) 30 568 (62.1) 6347 (67.3)
  Diabetes, n (%) 13 717 (27.9) 3695 (39.2)
  Cancer, n (%) 4558 (9.3) 1443 (15.3)
  Cardiovascular 
disease, n (%)
10 399 (21.1) 3417 (36.2)
  Cerebrovascular 
disease, n (%)
5192 (10.5) 1836 (19.5)
  Dementia, n (%) 5350 (10.9) 1953 (20.7)
  Chronic kidney 
disease, n (%)
9573 (21.9) 3042 (34.9)
  Peripheral artery 
disease, n (%)
1411 (2.9) 543 (5.8)
  HIV, n (%) 504 (1.0) 141 (1.5)
  Pneumonia, n (%) 765 (1.6) 336 (3.6)
  COPD, n (%) 7666 (15.6) 2429 (25.8)
Contextual factors
  ADI rank category, n (%)
   0–33.3 10 248 (20.8) 1785 (18.9)
   33.4–366.6 20 861 (42.4) 3643 (38.6)
   66.7–100 18 129 (36.8) 4000 (42.4)
Testing capacity
  COVID-19 testing 
capacity (per 10 000 
people), mean (SD)
3.1 (1.9) 2.8 (1.8)
Hospital occupancy
  Hospital occupancy 
(%), mean (SD)
37.0 (10.8) 38.1 (10.5)
ADI, Area Deprivation Index; COPD, chronic obstructive pulmonary disease.
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cancer, cardiovascular disease, cerebrovascular disease, 
chronic kidney disease, chronic obstructive pulmo-
nary disease (COPD), dementia, diabetes mellitus, HIV, 
hypertension, peripheral artery disease and pneumonia. 
Cancer, cardiovascular disease, cerebrovascular disease, 
dementia, HIV, peripheral artery disease, pneumonia and 
COPD were identified in the 2 years prior to testing posi-
tive for COVID-19 through International Classification 
of Diseases, 10th Version, Clinical Modification diagnosis 
codes.18 20 Chronic kidney disease was defined as baseline 
estimated glomerular filtration rate (eGFR) lower than 
60 mL/min/1.73 m2. Baseline eGFR was calculated using 
the Chronic Kidney Disease Epidemiology Collaboration 
(CKD- EPI) equation21 and was assessed as the veteran’s 
last outpatient value prior to the date of first COVID-19 
test positive. Participants who had no measurement of 
baseline eGFR (n=5447, 11.1% for veterans with COVID-
19; n=717, 7.6% for hospitalised veterans with COVID-
19) were assumed to have no chronic kidney disease. 
Diabetes was defined as any use of antihyperglycaemic 
medications22 23 or incidence of haemoglobin A1C 
greater or equal to 6.5%.24 Hypertension was defined as 
median systolic blood pressure greater than or equal to 
130 mm Hg or median diastolic blood pressure greater 
than or equal to 80 mm Hg in 1 year.25 Participants who 
had no measurement of blood pressure (n=2699, 5.5% 
for veterans with COVID-19; n=235, 2.5% for hospital-
ised veterans with COVID-19) were assumed to have no 
chronic kidney disease. ADI is a composite measure of a 
geographical location’s socioeconomic disadvantage, and 
ranges from 0 (low disadvantage) to 100 (high disadvan-
tage). County- level ADI of the participants was assigned 
based on the participant’s FIPS code of residence loca-
tion at the first COVID-19 positive test date. Mean imputa-
tion was applied to missing values of covariates including 
BMI (missing=111, 0.2% of veterans with COVID-19; 
missing=11, 0.1% of hospitalised veterans with COVID-19) 
and ADI (missing=1303, 2.6% of veterans with COVID-19; 
missing=88, 1.0% of hospitalised veterans with COVID-
19). COVID-19 testing capacity was calculated as 7- day 
averages of the number of COVID-19 tests conducted in 
a hospital system divided by the total number of veterans 
served in that hospital system in the last calendar year. 
Hospital occupancy rate was defined as the percentage 
of beds occupied by hospitalised patients in a hospital 
system within a calendar week. COVID-19 testing capacity 
and hospital occupancy rate were linked to the veterans 
by the hospital system in which the individuals had their 
first positive COVID-19 test.
Statistical analyses
We calculated and plotted 7- day moving averages of crude 
and standardised 30- day mortality and hospitalisation 
rates in COVID-19- positive participants, as well as 30- day 
mortality rates in hospitalised COVID-19- positive partici-
pants. The 7- day range included the current day, and the 
3 days before and after. Standardised rates were adjusted 
for age, race, gender, health behaviours (smoking status 
and BMI), comorbidities and ADI through indirect stan-
dardisation.26 The standardisation was based on the ratio 
difference between expected and observed number of 
outcomes, where the expected number of outcomes was 
estimated from individual- level logistic regressions.
To understand driving factors of the temporal tends 
in the outcomes, we decomposed the contribution of 
the changes in key participant characteristics to changes 
in the observed rates of outcomes over time. We first 
constructed individual- level logistic regression models for 
the different outcomes using four sets of factor domains: 
demographics (age, race and gender), health character-
istics (BMI, diabetes, cancer, cardiovascular disease, cere-
brovascular disease, chronic kidney disease, dementia, 
HIV, hypertension, peripheral artery disease, pneumonia 
and smoking status), contextual factors (ADI), COVID-19 
testing capacity and hospital occupancy rate. Hospital 
occupancy rate was not included as a predictor of hospi-
talisation since they are measuring the same variable. For 
each individual, we then computed the expected proba-
bilities of the outcome based on a participants observed 
characteristics and under a reference characteristics set, 
where probability of the outcome was minimised (age was 
set as 0, and other categorical variables were set to be the 
reference group). We estimated the additive contribution 
of the six sets of factor domains to the estimated rates 
of the outcome using decomposition analysis.27 Then the 
change in outcome rates between the first (20 March–19 








30- day mortality among 
hospitalised
COVID-19 patients, n (%)
20 March–19 April 5896 13.6 33.8 23.5
20 April–19 May 6685 12.3 17.2 17.0
20 May–19 June 4824 7.1 20.0 12.6
20 June–19 July 13 084 4.9 17.4 11.8
20 July–19 August 11 874 5.2 15.8 11.1
20 August–19 September 6875 4.4 17.0 10.8
Overall 49 238 7.2 19.1 14.8
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April) and the last (20 August–19 September) 30- day 
periods associated with each domain were calculated by 
taking the difference of the contributions between the 
two periods.
All statistical tests were two sided, and a p- value less 
than 0.05 or a 95% CI that did not contain unity was 
considered statistically significant. Statistical analyses and 
data visualisation were performed using SAS Enterprise 
Guide V.7.1 and R V.4.0.2.28 The participants were not 
involved in the design, conduct, reporting or dissemina-
tion plans of the study.
Patient and public involvement
No patients were involved in developing the hypothesis, 
the specific aims or the research questions, nor were they 
involved in developing plans for design or implementa-
tion of the study. No patients were involved in the inter-
pretation or writing up of results.
RESULTS
Between 20 March 2020 and 19 September 2020, we iden-
tified 49 238 US veterans who tested positive for COVID-19 
and 9 428 US veterans hospitalised with COVID-19. Char-
acteristics of the two cohorts are reported in table 1. 
Among individuals with COVID-19, the median age was 
63.3 years (IQR 49.8–73.1 years); 60.6% were white, 
33.9% were black, and 11.5% were women. Among hospi-
talised individuals, the median age was 70.6 years (IQR 
61.2–76.8 years); 53.6% were white, 40.4% were black, 
and 6.0% were women.
Temporal trends in 30-day mortality and hospitalisation rates
Between 20 March 2020 and 19 September 2020 and 
among individuals with a COVID-19- positive test, the 
30- day mortality rate dropped by 9.2% from 13.6% to 
4.4%; the hospitalisation rate dropped by 16.8% from 
33.8% to 17.0% (table 2 and figure 1). Among hospital-
ised individuals with COVID-19, the 30- day mortality rate 
dropped by 12.7% from 23.5% to 10.8% (table 2 and 
figure 1). After accounting for demographics, contextual 
factors, health characteristics, COVID-19 testing capacity 
and hospital occupancy, standardised rates showed consis-
tent decline during the period (figure 1).
Between 20 March 2020 and 19 September 2020 and 
among hospitalised individuals with COVID-19, we 
observed consistent decline in healthcare resource use 
including decline in rates of intensive care unit (ICU) 
admission, mechanical ventilator use and length of 
hospital stay (online supplemental table 1). The rate of 
ICU stay dropped by 4% from 35.6% to 31.6%; the rate of 
mechanical ventilator use dropped by 11.3% from 20.6% 
to 9.3%; the mean length of stay dropped by 4.2 days 
from 13.8 to 9.6 days.
Predictors of 30-day mortality and hospitalisation
Adjusted ORs for the association between potential 
predictors and risk of 30- day mortality and hospital-
isation among veterans with COVID-19, as well as risk 
of 30- day mortality among hospitalised veterans with 
COVID-19 are presented in table 3. Among veterans with 
COVID-19, older age, black and other race, male gender, 
current smoker, diabetes, cancer, cardiovascular disease, 
dementia, chronic kidney disease, pneumonia, COPD 
Figure 1 Temporal trends of COVID-19 30- day mortality 
and hospitalisation among US Veterans. (A,B) Thirty- day 
mortality and hospitalisation rates in US Veterans who 
had a positive COVID-19 test (n=29 528). (C) Thirty- day 
mortality rate in hospitalised US veterans with a positive 
COVID-19 test (n=6449). Fully standardised rates were 
adjusted for, demographics (age, race and gender), health 
characteristics (smoking status, Body Mass Index, cancer, 
cardiovascular disease, chronic kidney disease, dementia, 
type 2 diabetes mellitus, HIV, hypertension, peripheral artery 
disease, pneumonia and stroke), contextual factors (ADI), 
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and higher hospital occupancy rate were associated with 
higher risk of 30- day mortality and hospitalisation; higher 
COVID-19 testing capacity was associated with lower risk 
of 30- day mortality and hospitalisation. Among hospital-
ised veterans with COVID-19, older age, male gender, 
obesity, current smoker, diabetes, cardiovascular disease, 
chronic kidney disease, dementia and higher hospital 
occupancy rate were associated with higher risk of 30- day 
mortality; higher COVID-19 testing capacity was associ-
ated with lower risk of 30- day mortality. The models for 
30- day mortality and hospitalisation among those who 
tested positive, and the model for 30- day mortality among 




Hospitalised veterans with 
COVID-19
30- day mortality Hospitalisation 30- day mortality
Demographics
  Age 1.08 (1.07 to 1.08) 1.02 (1.02 to 1.02) 1.06 (1.06 to 1.07)
Race (reference=white)
  Black 1.11 (1.01 to 1.22) 1.64 (1.56 to 1.74) 1.03 (0.90 to 1.18)
  Other 1.33 (1.12 to 1.58) 1.58 (1.42 to 1.76) 1.20 (0.92 to 1.57)
  Sex, women (reference=men) 0.52 (0.40 to 0.67) 0.74 (0.67 to 0.82) 0.72 (0.47 to 1.06)
Health characteristics
  BMI category (reference=normal wt)
  Underweight (<18.5 kg/m2) 1.03 (0.64 to 1.59) 1.26 (0.92 to 1.71) 0.67 (0.29 to 1.38)
  Overweight (25–<30 kg/m2) 0.89 (0.80 to 1.00) 0.98 (0.91 to 1.06) 1.07 (0.90 to 1.29)
  Obesity (>18.5 kg/m2) 1.02 (0.92 to 1.15) 1.05 (0.98 to 1.13) 1.24 (1.03 to 1.49)
Smoking status (reference=never smoker)
  Former smoker 1.15 (1.05 to 1.25) 1.01 (0.96 to 1.07) 1.11 (0.97 to 1.28)
  Current smoker 1.12 (0.99 to 1.27) 1.11 (1.03 to 1.19) 1.21 (1.00 to 1.46)
  Hypertension 0.87 (0.80 to 0.94) 1.10 (1.04 to 1.16) 0.81 (0.70 to 0.92)
  Diabetes 1.37 (1.26 to 1.49) 1.23 (1.16 to 1.29) 1.15 (1.00 to 1.31)
  Cancer 1.10 (0.99 to 1.22) 1.36 (1.27 to 1.47) 1.03 (0.88 to 1.21)
  Cardiovascular disease 1.17 (1.07 to 1.27) 1.43 (1.35 to 1.52) 1.15 (1.00 to 1.31)
  Cerebrovascular disease 1.09 (0.98 to 1.20) 1.38 (1.29 to 1.48) 1.04 (0.90 to 1.21)
  Dementia 1.81 (1.65 to 2.00) 1.52 (1.41 to 1.63) 1.37 (1.18 to 1.59)
  Chronic kidney disease 1.48 (1.36 to 1.61) 1.27 (1.20 to 1.35) 1.47 (1.28 to 1.68)
  Peripheral arterial disease 1.09 (0.92 to 1.29) 1.31 (1.16 to 1.48) 1.17 (0.92 to 1.47)
  HIV 1.05 (0.67 to 1.58) 1.50 (1.22 to 1.85) 1.23 (0.71 to 2.03)
  Pneumonia 1.44 (1.15 to 1.80) 2.00 (1.71 to 2.35) 1.22 (0.90 to 1.62)
  COPD 1.21 (1.10 to 1.32) 1.40 (1.31 to 1.49) 0.96 (0.83 to 1.11)
Contextual factors
  ADI rank (reference=1–33.2)
  33.3–66.6 0.99 (0.89 to 1.10) 1.03 (0.96 to 1.10) 0.94 (0.79 to 1.11)
  66.7–100.0 1.04 (0.93 to 1.16) 1.16 (1.09 to 1.25) 0.92 (0.77 to 1.09)
COVID-19 testing capacity
  COVID-19 testing capacity (per 10 
000 veterans)
0.92 (0.90 to 0.94) 0.95 (0.94 to 0.96) 0.90 (0.86 to 0.93)
Hospital occupancy
  Hospital occupancy rate (an 
increase of 10%)
1.05 (1.01 to 1.08) Not included 1.08 (1.02 to 1.15)
  C- statistics 0.834 0.718 0.746
ADI, Area Deprivation Index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.
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hospitalised achieved reasonably good predictive perfor-
mance, with the c- statistics of 0.834, 0.718 and 0.746, 
respectively. The c- statistics for nested models, showing 
the predictive performance improvement when adding 
different variable sets, are included in online supple-
mental table 2.
Temporal change of predictors of 30-day mortality and 
hospitalisation
The demographic, health and contextual characteris-
tics as well as hospital occupancy and testing capacity in 
each 1- month interval after 20 March 2020 and before 
19 September 2020 are described in figures 2 and 3 and 
online supplemental table 3A,B. We observed substan-
tial decline in percent of black patients over time in 
both individuals with COVID-19 (from 47.2% to 25.5%, 
dropping by 21.7%) and hospitalised individuals with 
COVID-19 (from 54.4% to 28.2%, dropping by 26.3%). 
The prevalence of comorbidities was consistently 
dropping between the two periods in individuals with 
COVID-19; the overall trend of comorbidity prevalence 
was still declining while less consistent in hospitalised 
individuals with COVID-19. In both of two cohorts, the 
percent of individuals living in disadvantaged neigh-
bourhood (higher ADI) and COVID-19 testing capacity 
Figure 2 Change in predictors of 30- day mortality and hospitalisation among US veterans with COVID-19 between 20 
March and 19 April 2020 and 20 August and 19 September 2020. The yellow dots represent the prevalence of predictors in 20 
March–19 April 2020, while the green dots represent the prevalence of predictors in 20 August–19 September 2020. In the delta 
column, blue text indicates that the change of predictor leads to decrease in mortality and hospitalisation rates, while red text 
indicates the change of predictor leads to decrease in mortality and hospitalisation rates. ADI, Area Deprivation Index; COPD, 
chronic obstructive pulmonary disease.
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were increasing over time, while hospital occupancy was 
decreasing.
Contribution of changes in predictors to temporal changes in 
30-day mortality and hospitalisation rates
Decomposition analyses showed that from 20 March 2020 
to 19 September 2020 and among COVID-19- positive 
individuals, changes in demographics, health charac-
teristics, contextual characteristics, expansion of testing 
capacity and decreasing hospital occupancy contributed 
to 26.1%, 7.6%, 5.4%, −1.1% and 2.2% of the decline 
in 30- day mortality rates respectively. Altogether, these 
predictors accounted for 40.2% of the decline in 30- day 
mortality in veterans with COVID-19 (figure 4 and online 
supplemental table 4).
Changes in demographics, health characteristics and 
contextual characteristics, and expansion of testing 
capacity, and decreasing hospital occupancy contributed 
to 19.6%, 9.0%, −0.6% and 5.4% of the decline in hospi-
talisation rates. Altogether, they accounted for 33.3% 
of the decline in hospitalisation rates in veterans with 
COVID-19 (figure 4 and online supplemental table 4).
Among those hospitalised with COVID-19, changes in 
demographic, health characteristics, contextual char-
acteristics, expansion of testing capacity and decreasing 
Figure 3 Change in predictors of 30- day mortality among hospitalised US veterans with COVID-19 between 20 March and 
19 April 2020 and between 20 August and 19 September 2020. The yellow dots represent the prevalence of predictors in 20 
March–19 April 2020, while the green dots represent the prevalence of predictors in 20 August–19 September 2020. In the Δ 
column, the blue text indicates that the change of predictor leads to decrease in mortality rates, while the red text indicates the 
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hospital occupancy accounted for 23.6%, 2.4%, −0.8%, 
1.6% and 3.1% of the decline in 30- day mortality rate, 
respectively. All predictors collectively accounted for 
29.9% of the decline in 30- day mortality (figure 4 and 
online supplemental table 4).
DISCUSSION
This analysis of temporal trends of COVID-19 hospitalisa-
tion and mortality suggests substantial decline between 
March 2020 and September 2020. We also observed 
substantial shifts in the demographic and health charac-
teristics of those who tested positive for COVID-19 and 
in those who were hospitalised with a positive COVID-19 
test including substantial decline in the percentage of 
black people and comorbidity burden as well as increase 
in testing capacity and reduction in hospital occupancy 
rates. Around 40.2% of the decline in mortality rates and 
33.3% of decline in hospitalisation rates were explained 
by changes in the underlying characteristics of people 
who tested positive for COVID-19. Around 29.9% of 
the decline in mortality rates among hospitalised indi-
viduals was explained by changes in their underlying 
characteristics.
Our analysis highlights the influence of individual- level 
demographic and health characteristics on hospitalisa-
tion and mortality rates in COVID-19. The contribution of 
changes in testing capacity to these outcomes (although 
small) was measurable. The contribution of hospital occu-
pancy rates to decline in mortality rates also highlights the 
importance of this variable as policy makers and health 
systems continue to optimise the public health response 
to this pandemic and may also be useful in preparing for 
and mitigating the impact of future pandemics.
Slightly more than half of decline in rates was not 
predicted by the explanatory variables in our models 
and likely reflects the influence of factors that are not 
accounted for in our approach including improvement in 
medical care (to the extent that it may have influenced the 
outcomes), a putative seasonality effect and the potential 
influence of the broader public health policy measures 
on these outcomes. In particular, it has been postulated 
that severity of COVID-19 may be proportionate to the 
viral inoculum which initiates the infection in the human 
host, and it is plausible that public health policies (eg, 
physical distancing, masking, etc) may have reduced the 
viral inoculum in some infected individuals and might 
have consequently resulted in less severe COVID-19 (and 
reduced hospitalisation and mortality)—a hypothesis 
referred to as the variolation of coronavirus.29
Our findings not only provide insight into the dynamic 
changes of key indicators of the COVID-19 pandemic 
(mortality and hospitalisation rates) but also estimate of 
the influence of individual and contextual parameters on 
these indicators. The synergistic influence of both indi-
vidual and contextual factors cannot be overstated.30 31 
The COVID-19 pandemic has brought to prominence the 
complex interplay of several dynamic drivers including 
individual- level demographic and health characteristics, 
Figure 4 Contribution of changes in demographics, health characteristics, testing capacity, hospital occupancy and contextual 
factors, and epidemiological changes to changes in 30- day mortality and hospitalisation rates between 20 March and 19 
April 2020 and between 20 August and 19 September 2020. The red dot represents the observed change in rate of outcomes 
between the two periods, and the blue dot represents the change predicted based on demographics, health, contextual 
characteristics, COVID-19 testing capacity and hospital occupancy. Hospital occupancy is not considered as predictor for the 
hospitalisation outcome model. Epidemiological changes collectively represent the difference between predicted and observed 
rates and reflect the summative contribution of factors that are not accounted for in prediction models.
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health system- level characteristics, the influence of socio-
economic factors and the broader contextual reality in 
which people live (public health response, etc)—all collec-
tively shape the ultimate health outcomes of COVID-19. 
Continued effort to surveil temporal trends of key indica-
tors of this global pandemic and careful analysis of drivers 
of any temporal change are needed to inform ongoing 
effort to optimise the management of this so far unabated 
pandemic and to guide development of better mitigation 
plans for future pandemics.
While we investigated the temporal trends of COVID-19 
mortality and hospitalisation rates within the US veteran 
population, some important differences between our 
cohort and the general US population are noteworthy 
to better contextualise the broader implications of our 
findings. In our cohort, the median age was 63.6 years, 
the percentages of white and black race were 60.6% 
and 33.9%, 11.5% were women and 17.6% were current 
smokers; whereas in the US general population, the 
median age is 38.1 years, the percentages of white and 
black race are 60.1% and 13.4%, 50.8% are women and 
13.7% are current smokers.32 33
A key strength of this analysis is the use of individual- 
level data from the US Department of VA, which operates 
the largest nationally integrated healthcare system in the 
USA, and use of advanced methods to decompose the 
influence of changes in demographics and health char-
acteristics on temporal trends. In addition to accounting 
for individual- level demographic and health characteris-
tics, our analyses also accounted for contextual variables, 
testing capacity and measures of hospital occupancy 
rates—as important determinants of outcomes in this 
pandemic.
This analysis has several limitations. While we used 
validated definitions to identify covariates, we cannot 
completely rule out misclassification bias. While we 
accounted for known predictors, our analyses do not 
account for predictors that are not measured in the 
data sets including improvement in medical care as 
the pandemic progressed, and other unmeasured or 
unknown variables.
In sum, between March 2020 and September 2020, 
we observed substantial decline in 30- day mortality and 
hospitalisation among COVID-19- positive individuals and 
substantial decline in 30- day mortality among those hospi-
talised with COVID-19. The temporal decline in these 
outcomes was partially explained by changes in under-
lying demographic, health and contextual characteristics, 
as well as expansion of testing capacity, and reduction in 
hospital occupancy rates. The results may be helpful in 
informing effort to optimise the collective public health 
response to this ongoing pandemic and guide plans to 
mitigate the impact of future pandemics.
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